{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Mereo BioPharma Group plc"},"Symbol":{"label":"Symbol","value":"MREO"},"Address":{"label":"Address","value":"ONE CAVENDISH PLACE,4TH FLOOR, LONDON, W1G 0QF, United Kingdom"},"Phone":{"label":"Phone","value":"+44 3330237300"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod."},"CompanyUrl":{"label":"Company Url","value":"https://www.mereobiopharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Denise Vera Scots-Knight","title":"Chief Executive Officer & Director"},{"name":"John A. Lewicki","title":"Chief Scientific Officer"},{"name":"Suba Krishnan","title":"Senior Vice President-Clinical Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}